The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Collaboration combines Lunit's AI expertise with Agilent's diagnostic leadership to revolutionize biomarker testing and enhance precision medicine capabilities
Importantly, the combination of giredestrant and everolimus was well tolerated
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
Merck opens first climate-neutral manufacturing facility in Ireland
Conducted entirely in Europe across forty sites in five countries, this rigorous study met all clinical endpoints
Subscribe To Our Newsletter & Stay Updated
